Understanding how cells respond to DNA replication issues in fission yeast
DNA Replication Checkpoint in Fission Yeast
['FUNDING_OTHER'] · WRIGHT STATE UNIVERSITY · NIH-11015026
This study is looking at how certain cells, like those in fission yeast, respond to problems during DNA copying to keep our genetic material safe, and it aims to help us understand how these processes work in human cells too.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WRIGHT STATE UNIVERSITY (nih funded) |
| Locations | 1 site (DAYTON, UNITED STATES) |
| Trial ID | NIH-11015026 on ClinicalTrials.gov |
What this research studies
This research investigates a critical cell signaling pathway that monitors DNA replication in fission yeast, which serves as a model for human cells. It aims to understand how cells activate responses to prevent DNA damage and maintain genomic stability when replication is disrupted. By studying specific mutants, the research will explore the mechanisms behind the initiation of these cellular responses and how they protect DNA during stress. This work combines genetic and biochemical methods to uncover essential details about the checkpoint's function.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research include cancer patients undergoing chemotherapy who may have varying responses to treatment based on their DNA replication checkpoint status.
Not a fit: Patients with non-cancerous conditions or those not undergoing chemotherapy may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatments by enhancing the effectiveness of anticancer drugs.
How similar studies have performed: Previous research has shown success in understanding DNA replication checkpoints in other model organisms, suggesting potential for breakthroughs in cancer treatment.
Where this research is happening
DAYTON, UNITED STATES
- WRIGHT STATE UNIVERSITY — DAYTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: XU, YONGJIE — WRIGHT STATE UNIVERSITY
- Study coordinator: XU, YONGJIE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer, Anti-Cancer Agents, anti-cancer drug, cancer chemotherapy, Cancer Drug